Elanco Animal Health Eyes Growth, Deleveraging as Quattro and Zenrelia Gain Ground

Elanco reported 10% quarterly growth and is targeting mid-single-digit revenue growth, high-single-digit EBITDA growth and low-double-digit EPS growth over the next three years, while generating $1 billion in cash through 2028.

Quattro and Zenrelia are gaining rapid adoption across parasite and dermatology markets, with international expansion expected to support growth through 2027; Befrena could also become a major driver once supply capacity increases.

Elanco plans to reduce leverage from roughly six-to-seven times after the Bayer acquisition to about three times by year-end and the two-times range next year, while improving margins and prioritizing debt reduction over major acquisitions.

Elanco Animal Health NYSE: ELAN President and CEO Jeff Simmons outlined the company’s growth strategy, product launches, deleveraging plans and outlook for its pet health and farm animal businesses during the Bank of America Healthcare Conference in London. Simmons said Elanco delivered 10% reported growth in its most recently completed quarter, split evenly between Farm Animal and Pet Health, as well as between U.S. and international markets and price and volume. He characterized the performance as “high-quality growth” and said the company remains focused on three priorities: growth, innovation and cash generation.

Elanco is targeting mid-single-digit revenue growth, high-single-digit EBITDA growth and low-double-digit earnings-per-share growth over the next three years, according to Simmons. The company has also committed to generating $1 billion in cash through 2028, expanding margins annually and reducing leverage. Simmons said Elanco’s leverage, which reached roughly six to seven times following its acquisition of Bayer’s animal health business, is expected to decline to about three times by year-end and move into the two-times range next year.

Addressing pricing concerns in animal health, Simmons said Elanco recorded 2% pricing growth in the first half of the year and saw price gains accelerate in July and August. He said the company’s ability to raise prices is tied to medical differentiation, particularly for products addressing conditions important to pet owners. Elanco surveyed 1,400 U.S. pet owners at the end of May, and 86% said they expected to spend the same amount or more on pet health, according to Simmons. While consumers may reduce spending on food, supplements and hard goods, he said the company has not seen a comparable pullback in spending on health-related products. Simmons said the company sees no broad price war in the industry, though targeted promotions occur, especially among corporate veterinary groups. Elanco is underrepresented with corporate clinic groups, he said, but does not view that channel as necessary to drive its growth plan in the near term. He also highlighted Elanco’s over-the-counter presence from the Bayer acquisition. The company sells through retailers and online platforms including Chewy, Amazon and Walmart, which Simmons said provides access to pet owners who do not regularly visit veterinarians and may be more price-sensitive.

Simmons identified Quattro, Elanco’s parasite treatment for dogs, as a major growth opportunity. He said the product has reached more than half of U.S. veterinary clinics and has become the fastest blockbuster product in Elanco’s history. The company has said Quattro has exceeded $100 million in sa...